1. Barrdahl M, Rudolph A, Hopper JL, Southey MC, Broeks A, Fasching PA, Beckmann MW, Gago-Dominguez M, Castelao JE et al: Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. Int. J. Cancer 141, 1830-1840, 2017. PMID 28670784

2. Day FR, Thompson DJ, Helgason H, Chasman DI, Finucane H, Sulem P, Ruth KS, Whalen S, Sarkar AK et al: Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat. Genet. 49, 834-841, 2017. PMID 28436984

3. Decker B, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK, Wang Q, Ahmed S, Baynes C, Conroy DM, Brown J, Luben R, Ostrander EA, Pharoah PD, Dunning AM, Easton DF Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. J. Med. Genet. 54, 732-741, 2017. PMID 28779002

4. Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD et al: Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget 8, 50930-50940, 2017. PMID 28881617

5. Fagerholm R, Khan S, Schmidt MK, Garcia-Closas M, Heikkila P, Saarela J, Beesley J, Jamshidi M, Aittomaki K et al: TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget 8, 18381-18398, 2017. PMID 28179588

6. Glubb DM, Johnatty SE, Quinn MCJ, O’Mara TA, Tyrer JP, Gao B, Fasching PA, Beckmann MW, Lambrechts D et al: Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget 8, 64670-64684, 2017. PMID 29029385

7. Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham J, Aittomaki K, Andrulis IL et al: Body mass index and breast cancer survival: a Mendelian randomization analysis. Int. J. Epidemiol. 46, 1814-1822, 2017. PMID 29232439

8. James FR, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton JD, Pharoah PDP, Ali HR Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer 17, 657, 2017. PMID 28931370

9. Kar SP, Adler E, Tyrer J, Hazelett D, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bogdanova N et al: Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br. J. Cancer 116, 524-535, 2017. PMID 28103614

10. Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, Domchek SM, Robson M, Spurdle AB et al: Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J. Natl. Cancer Inst. 109, 2017. PMID 28376175

11. Liu G, Lee S, Lee AW, Wu AH, Bandera EV, Jensen A, Anne Rossing M, Moysich KB, Chang-Claude J et al: Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am. J. Epidemiol., 2017. PMID 28633381

12. Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG et al: Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. Br. J. Cancer 117, 734-743, 2017. PMID 28765617

13. Machiela MJ, Hofmann JN, Carreras-Torres R, Brown KM, Johansson M, Wang Z, Foll M, Li P, Rothman N et al: Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Eur Urol 72, 747-754, 2017. PMID 28797570

14. Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, Lemacon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A et al: Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92-94, 2017. PMID 29059683

15. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindstrom S, Hui S, Lemacon A, Soucy P, Dennis J et al: Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat. Genet., 2017. PMID 29058716

16. Muranen TA, Greco D, Blomqvist C, Aittomaki K, Khan S, Hogervorst F, Verhoef S, Pharoah PDP, Dunning AM, Shah M, et al: Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genet Med 19, 599-603, 2017. PMID 27711073

17. Newcombe PJ, Raza Ali H, Blows FM, Provenzano E, Pharoah PD, Caldas C, Richardson S Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival. Stat. Methods Med. Res. 26, 414-436, 2017. PMID 25193065

18. Ovarian Tumor Tissue Analysis Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, et al: Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol., e173290, 2017. PMID 29049607

19. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ et al: Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat. Genet. 49, 680-691, 2017. PMID 28346442
20. Praestegaard C, Jensen A, Jensen SM, Nielsen TS, Webb PM, Nagle CM, DeFazio A, Australian Ovarian Cancer Study G, Hogdall E et al: Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int. J. Cancer 140, 2422-2435, 2017. PMID 28063166

21. Reid BM, Permuth JB, Chen YA, Teer JK, Monteiro AN, Chen Z, Tyrer J et al: Integration of population-level genotype data with functional annotation reveals over-representation of long noncoding RNAs at ovarian cancer susceptibility loci. Cancer Epidemiol. Biomarkers Prev. 26, 116-125, 2017. PMID 28035019

22. Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J et al: Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat Commun 8, 15724, 2017. PMID 28598434

23. Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calleja F, Meeks H, Hallberg E et al: BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. 77, 2789-2799, 2017. PMID 28283652

24. Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, et al:, Australian Ovarian Cancer S No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiol. Biomarkers Prev. 26, 420-424, 2017. PMID 27677730

25. Sud A, Thomsen H, Law PJ, Forsti A, Filho M, Holroyd A, Broderick P, Orlando G, Lenive O, Wright L, Cooke R, Easton D, Pharoah P, Dunning A, Peto J, et al: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat Commun 8, 1892, 2017. PMID 29196614

26. Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F et al: Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol 2015.

27. Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S et al: Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet 2015, 24(19):5589-5602.

28. Blows FM, Ali HR, Dawson SJ, Le Quesne J, Provenzano E, Caldas C, Pharoah PD: Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays. Appl Immunohistochem Mol Morphol 2015.

29. Candido Dos Reis FJ, Lynn S, Ali HR, Eccles D, Hanby A, Provenzano E, Caldas C, Howat WJ, McDuffus LA, Liu B et al: Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine 2015, 2(7):681-689.

30. Candido Dos Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ et al: Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2015, 21(3):652-657.

31. Cheng TH, Thompson D, Painter J, O’Mara T, Gorman M, Martin L, Palles C, Jones A, Buchanan DD, Ko Win A et al: Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Sci Rep 2015, 5:17369.

32. Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, Qu X, Tsai YY, Jim HS, Chen Z et al: Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS One 2015, 10(6):e0128106.

33. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B et al: Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 2015.

34. Guo Q, Schmidt MK, Kraft P, Canisius S, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J et al: Identification of novel genetic markers of breast cancer survival. J Natl Cancer Inst 2015, 107(5).

35. Guo X, Long J, Zeng C, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Milne RL, Shu XO, Cai Q et al: Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2015.

36. Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, Johnson N, McDuffus LA, Miller J, Sawyer EJ et al: Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol Clin Res 2015, 1(1):18-32.

37. Jamshidi M, Fagerholm R, Khan S, Aittomaki K, Czene K, Darabi H, Li J, Andrulis IL, Chang-Claude J, Devilee P et al: SNP-SNP interaction analysis of NF-kappaB signaling pathway on breast cancer survival. Oncotarget 2015.

38. Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, Manchanda R, Easton DF, Jacobs I, Pharoah PP et al: A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet 2015, 52(7):465-475.

39. Johnatty S, Tyrer JP, Kar SP, Beesley J, Lu Y, Gao B, Fasching PA, Hein A, Ekici AB, Beckmann MW et al: Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clin Cancer Res 2015.

40. Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H, Antonenkova N, Chenevix-Trench G, Baker H, Bandera E et al: Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2015.

41. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ et al: Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet 2015, 47(8):888-897.

42. Lagergren K, Ek WE, Levine D, Chow WH, Bernstein L, Casson AG, Risch HA, Shaheen NJ, Bird NC, Reid BJ et al: Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett’s Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. PLoS One 2015, 10(9):e0138738.

43. Law MH, Bishop DT, Lee JE, Brossard M, Martin NG, Moses EK, Song F, Barrett JH, Kumar R, Easton DF et al: Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet 2015.

44. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, Li Q, Marks JR, Berchuck A, Lee JM et al: Common Variants at the CHEK2 Gene Locus and Risk of Epithelial Ovarian Cancer. Carcinogenesis 2015.

45. Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J, Chen Y, Karst A, Drapkin R et al: Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun 2015, 6:8234.

46. Lei J, Rudolph A, Moysich KB, Behrens S, Goode EL, Bolla MK, Dennis J, Dunning AM, Easton DF, Wang Q et al: Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Hum Genet 2015.

47. Lu Y, Cuellar G, Painter JN, Nyholt D, Australian Ovarian Cancer S, International Endogene C, Morris AP, Fasching PA, Hein A, Burghaus S et al: Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet 2015.

48. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker A, Australian National Endometrial Cancer Study G, Perry JR, Attia J et al: Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis. J Natl Cancer Inst 2015, 107(9).

49. O’Mara TA, Glubb DM, Painter JN, Cheng T, Dennis J, Australian National Endometrial Cancer Study G, Attia J, Holliday EG, McEvoy M, Scott RJ et al: Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocr Relat Cancer 2015, 22(5):851-861.

50. Pirie A, Guo Q, Kraft P, Canisius S, Eccles DM, Rahman N, Nevanlinna H, Chen C, Khan S, Tyrer J et al: Common germline polymorphisms associated with breast cancer specific survival. Breast Cancer Res 2015, 17(1):58.

51. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S et al: Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst 2015, 107(11).

52. Rudolph A, Fasching PA, Behrens S, Eilber U, Bolla MK, Wang Q, Thompson D, Czene K, Brand JS, Li J et al: A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. Breast Cancer Res 2015, 17(1):110.

53. Sobral-Leite M, Wesseling J, Smit VT, Nevanlinna H, van Miltenburg MH, Sanders J, Hofland I, Blows FM, Coulson P, Patrycja G et al: Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. BMC Med 2015, 13:156.

54. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L et al: Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol 2015.

55. Stone J, Thompson DJ, Dos Santos Silva I, Scott C, Tamimi RM, Lindstrom S, Kraft P, Hazra A, Li J, Eriksson L et al: Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Res 2015, 75(12):2457-2467.

56. Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Amin Al Olama A, Benlloch S et al: Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev 2015.

57. Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K et al: Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate 2015.

58. Thompson DJ, O’Mara TA, Glubb DM, Painter JN, Cheng T, Folkerd E, Doody D, Dennis J, Webb PM, Gorman M et al: CYP19A1 fine-mapping and Mendelian randomisation: estradiol is causal for endometrial cancer. Endocr Relat Cancer 2015.

59. Zhang B, Shu XO, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, Wang Q, Dennis J, Wen W, Long J et al: Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. J Natl Cancer Inst 2015, 107(11).

60. Abubakar M, Howat WJ, Daley F, Zabaglo L, McDuffus LA, Blows F, Coulson P, Raza Ali H, Benitez J, Milne R et al: High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. J Pathol Clin Res 2016, 2(3):138-153.

61. Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F, Benitez J, Milne R, Brenner H, Stegmaier C et al: Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res 2016, 18(1):104.

62. Ahmed M, Dorling L, Kerns S, Fachal L, Elliott R, Partliament M, Rosenstein BS, Vega A, Gomez-Caamano A, Barnett G et al: Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. Br J Cancer 2016.

63. 38 Blows FM, Ali HR, Dawson SJ, Le Quesne J, Provenzano E, Caldas C, Pharoah PD: Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays. Appl Immunohistochem Mol Morphol 2016, 24(3):221-226.

64. Chen MM, O’Mara TA, Thompson DJ, Painter JN, Australian National Endometrial Cancer Study G, Attia J, Black A, Brinton L, Chanock S, Chen C et al: GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. Hum Mol Genet 2016.

65. Cheng TH, Thompson DJ, O’Mara TA, Painter JN, Glubb DM, Flach S, Lewis A, French JD, Freeman-Mills L, Church D et al: Five endometrial cancer risk loci identified through genome-wide association analysis. Nat Genet 2016, 48(6):667-674.

66. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H et al: Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun 2016, 7:11375.

67. Cuellar-Partida G, Lu Y, Dixon SC, Australian Ovarian Cancer S, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E et al: Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 2016.

68. Darabi H, Beesley J, Droit A, Kar S, Nord S, Moradi Marjaneh M, Soucy P, Michailidou K, Ghoussaini M, Fues Wahl H et al: Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Sci Rep 2016, 6:32512.

69. Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN, Chenevix-Trench AG, Fasching PA, Beckmann MW et al: Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol 2016.

70. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E et al: Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet 2016, 48(4):374-386.

71. Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK et al: No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet 2016.

72. Fehringer G, Kraft P, Pharoah PD, Eeles RA, Chatterjee N, Schumacher FR, Schildkraut JM, Lindstrom S, Brennan P, Bickeboller H et al: Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Res 2016.

73. French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X et al: Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget 2016.

74. Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M et al: Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol 2016.

75. Ghoussaini M, French JD, Michailidou K, Nord S, Beesley J, Canisus S, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M et al: Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. Am J Hum Genet 2016.

76. Guo Y, Warren Andersen S, Shu XO, Michailidou K, Bolla MK, Wang Q, Garcia-Closas M, Milne RL, Schmidt MK, Chang-Claude J et al: Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Med 2016, 13(8):e1002105.

77. Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA et al: Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun 2016, 7:10979.

78. Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dork T, Hillemanns P, Preus L, Knutson KL, Wallace PK et al: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget 2016.

79. Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomaki K, Alducci E, Andrulis IL, Anton-Culver H et al: No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 2016, 141(2):386-401.

80. Horne HN, Chung CC, Zhang H, Yu K, Prokunina-Olsson L, Michailidou K, Bolla MK, Wang Q, Dennis J, Hopper JL et al: Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS One 2016, 11(8):e0160316.

81. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ et al: Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discov 2016.

82. Karami S, Han Y, Pande M, Cheng I, Rudd J, Pierce BL, Nutter EL, Schumacher FR, Kote-Jarai Z, Lindstrom S et al: Telomere structure and maintenance gene variants and risk of five cancer types. Int J Cancer 2016.

83. Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK et al: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 2016, 7:12675.

84. Lee AJ, Cunningham AP, Tischkowitz M, Simard J, Pharoah PD, Easton DF, Antoniou AC: Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med 2016.

85. Lee AW, Bomkamp A, Bandera EV, Jensen A, Ramus SJ, Goodman MT, Rossing MA, Modugno F, Moysich KB, Chang-Claude J et al: A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. Int J Cancer 2016.

86. Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL, Ovarian Cancer Association C: Evidence of a genetic link between endometriosis and ovarian cancer. Fertil Steril 2016, 105(1):35-43 e31-10.

87. Lei J, Rudolph A, Moysich KB, Behrens S, Goode EL, Bolla MK, Dennis J, Dunning AM, Easton DF, Wang Q et al: Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Hum Genet 2016, 135(1):137-154.

88. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, Embrace, McGuffog L et al: BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 2016, 108(2).

89. Muranen TA, Blomqvist C, Dork T, Jakubowska A, Heikkila P, Fagerholm R, Greco D, Aittomaki K, Bojesen SE, Shah M et al: Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium. Breast Cancer Res 2016, 18(1):98.

90. Muranen TA, Greco D, Blomqvist C, Aittomaki K, Khan S, Hogervorst F, Verhoef S, Pharoah PD, Dunning AM, Shah M et al: Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genet Med 2016.

91. Ong JS, Cuellar-Partida G, Lu Y, Ovarian Cancer Study A, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E et al: Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol 2016.

92. Painter JN, O’Mara TA, Marquart L, Webb PM, Attia J, Medland SE, Cheng T, Dennis J, Holliday EG, McEvoy M et al: Genetic risk score Mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2016.

93. Pelttari LM, Khan S, Vuorela M, Kiiski JI, Vilske S, Nevanlinna V, Ranta S, Schleutker J, Winqvist R, Kallioniemi A et al: RAD51B in Familial Breast Cancer. PLoS One 2016, 11(5):e0153788.

94. Permuth JB, Pirie A, Ann Chen Y, Lin HY, Reid BM, Chen Z, Monteiro A, Dennis J, Mendoza-Fandino G, Group AS et al: Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 2016, 25(16):3600-3612.

95. Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z, Aocs Study G, Chenevix-Trench G, Fasching PA, Beckmann MW et al: Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget 2016, 7(45):72381-72394.

96. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, Orr N, Cox A et al: Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res 2016, 18(1):22.

97. Pharoah PD, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K, Australian Ovarian Cancer Study G, Bogdanova N, Cicek MS et al: PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 2016, 108(3).

98. Praestegaard C, Kjaer SK, Nielsen TS, Jensen SM, Webb PM, Nagle CM, Hogdall E, Risch HA, Rossing MA, Doherty JA et al: The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiol 2016, 41:71-79.

99. Reid BM, Permuth JB, Chen YA, Teer JK, Monteiro AN, Chen Z, Tyrer J, Berchuck A, Ovarian Cancer Association C, Chenevix-Trench G et al: Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 2016.

100. Scarbrough PM, Weber RP, Iversen ES, Brhane Y, Amos CI, Kraft P, Hung RJ, Sellers TA, Witte JS, Pharoah P et al: A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2016, 25(1):193-200.

101. Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers H, Waisfisz Q, Hollestelle A, Schutte M et al: Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol 2016, 34(23):2750-2760.

102. Shi J, Zhang Y, Zheng W, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Dennis J, Lush M, Milne RL et al: Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer 2016.

103. Southey MC, Goldgar DE, Winqvist R, Pylkas K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ et al: PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 2016.

104. Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A et al: No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiol Biomarkers Prev 2016.

105. Sung H, Garcia-Closas M, Chang-Claude J, Blows FM, Ali HR, Figueroa J, Nevanlinna H, Fagerholm R, Heikkila P, Blomqvist C et al: Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. Br J Cancer 2016, 114(3):298-304.

106. Thompson DJ, O’Mara TA, Glubb DM, Painter JN, Cheng T, Folkerd E, Doody D, Dennis J, Webb PM, Australian National Endometrial Cancer Study G et al: CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer 2016, 23(2):77-91.

107. Usset JL, Raghavan R, Tyrer JP, McGuire V, Sieh W, Webb P, Chang-Claude J, Rudolph A, Anton-Culver H, Berchuck A et al: Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiol Biomarkers Prev 2016, 25(5):780-790.

108. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J et al: Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One 2016, 11(7):e0158801.

109. Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O’Brien SW et al: The BRCA1-Delta11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res 2016, 76(9):2778-2790.

110. Winham SJ, Pirie A, Chen YA, Larson MC, Fogarty ZC, Earp MA, Anton-Culver H, Bandera EV, Cramer D, Doherty JA et al: Investigation of exomic variants associated with overall survival in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2016.

111. Wyszynski A, Hong CC, Lam K, Michailidou K, Lytle C, Yao S, Zhang Y, Bolla MK, Wang Q, Dennis J et al: An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Hum Mol Genet 2016.

112. Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL et al: Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 2016, 18(1):64.

113. Zhao Z, Wen W, Michailidou K, Bolla MK, Wang Q, Zhang B, Long J, Shu XO, Schmidt MK, Milne RL et al: Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 2016, 27(5):679-693.

114. Stegeman S, Amankwah E, Klein K, O’Mara TA, Kim D, Lin HY, et al. A large scale analysis of genetic variants within putative miRNA binding sites in prostate cancer. Cancer Discov 2015.

115. Rudolph A, Milne RL, Truong T, Knight JA, Seibold P, Flesch-Janys D, et al. Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. Int J Cancer 2015;136(6):E685-96.

116. Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, et al. Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiol Biomarkers Prev 2015.

117. Painter JN, O’Mara TA, Batra J, Cheng T, Lose FA, Dennis J, et al. Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 2015;24(5):1478-92.

118. Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, et al. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Hum Mol Genet 2015.

119. Moir-Meyer GL, Pearson JF, Lose F, Australian National Endometrial Cancer Study G, Scott RJ, McEvoy M, et al. Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition. Hum Genet 2015;134(3):269-78.

120. Modelska A, Turro E, Russell R, Beaton J, Sbarrato T, Spriggs K, et al. The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape. Cell Death Dis 2015;6:e1603.

121. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015.

122. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 2015;107(5).

123. Lin WY, Camp NJ, Ghoussaini M, Beesley J, Michailidou K, Hopper JL, et al. Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet 2015;24(1):285-98.

124. Lei J, Rudolph A, Moysich KB, Rafiq S, Behrens S, Goode EL, et al. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Res 2015;17(1):522.

125. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, et al. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecol Oncol 2015;136(3):542-8.

126. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015;47(2):164-71.

127. Kabisch M, Lorenzo Bermejo J, Dunnebier T, Ying S, Michailidou K, Bolla MK, et al. Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis 2015;36(2):256-71.

128. Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, et al. Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. Am J Hum Genet 2015;96(1):5-20.

129. Fagerholm R, Schmidt MK, Khan S, Rafiq S, Tapper W, Aittomaki K, et al. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget 2015.

130. Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, et al. Cell Type Specific Enrichment Of Risk Associated Regulatory Elements At Ovarian Cancer Susceptibility Loci. Hum Mol Genet 2015.

131. Carvajal-Carmona LG, O’Mara TA, Painter JN, Lose FA, Dennis J, Michailidou K, et al. Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Hum Genet 2015;134(2):231-45.

132. Barrett JH, Taylor JC, Bright C, Harland M, Dunning AM, Akslen LA, et al. Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. Int J Cancer 2015;136(6):1351-60.

133. Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal D, et al. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 2015.

134. Wishart GC, Rakha E, Green A, Ellis I, Ali HR, Provenzano E, et al. Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. BMC Cancer 2014;14:908.

135. Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet 2014;23(17):4703-9.

136. Schoeps A, Rudolph A, Seibold P, Dunning AM, Milne RL, Bojesen SE, et al. Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. Genet Epidemiol 2014;38(1):84-93.

137. Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet 2014;10(4):e1004285.

138. Saunders EJ, Dadaev T, Leongamornlert DA, Jugurnauth-Little S, Tymrakiewicz M, Wiklund F, et al. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet 2014;10(2):e1004129.

139. Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, et al. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Hum Mol Genet 2014.

140. Perry JR, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature 2014;514(7520):92-7.

141. Painter JN, O’Mara TA, Batra J, Cheng T, Lose FA, Dennis J, et al. Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 2014.

142. Newcombe P, Raza Ali H, Blows F, Provenzano E, Pharoah P, Caldas C, et al. Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival. Stat Methods Med Res 2014.

143. Moir-Meyer GL, Pearson JF, Lose F, The Australian National Endometrial Cancer Study G, Scott RJ, McEvoy M, et al. Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition. Hum Genet 2014.

144. Milne RL, Herranz J, Michailidou K, Dennis J, Tyrer JP, Zamora MP, et al. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet 2014;23(7):1934-46.

145. Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menendez-Rodriguez P, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2014.

146. Lu Y, Ek WE, Whiteman D, Vaughan TL, Spurdle AB, Easton DF, et al. Most common ‘sporadic’ cancers have a significant germline genetic component. Hum Mol Genet 2014.

147. Li Q, Stram A, Chen C, Kar S, Gayther S, Pharoah P, et al. Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Hum Mol Genet 2014.

148. Li J, Lindstrom LS, Foo JN, Rafiq S, Schmidt MK, Pharoah PD, et al. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun 2014;5:4051.

149. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, et al. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecol Oncol 2014.

150. Larson NB, Jenkins GD, Larson MC, Vierkant RA, Sellers TA, Phelan CM, et al. Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer. Eur J Hum Genet 2014;22(1):126-31.

151. Kobel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer 2014;111(12):2297-307.

152. Khan S, Greco D, Michailidou K, Milne RL, Muranen TA, Heikkinen T, et al. MicroRNA related polymorphisms and breast cancer risk. PLoS One 2014;9(11):e109973.

153. Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, et al. Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Mol Nutr Food Res 2014.

154. Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, et al. Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Res 2014;16(3):R51.

155. Jervis S, Song H, Lee A, Dicks E, Tyrer J, Harrington P, et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J Med Genet 2014;51(2):108-13.

156. Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, et al. The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 2014;106(10).

157. Horne HN, Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, et al. Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res Treat 2014;143(1):181-7.

158. Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, et al. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun 2014;4:4999.

159. Etemadi A, Abnet CC, Kamangar F, Islami F, Khademi H, Pourshams A, et al. Impact of body size and physical activity during adolescence and adult life on overall and cause-specific mortality in a large cohort study from Iran. Eur J Epidemiol 2014;29(2):95-109.

160. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer S, et al. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 2014;133(5):481-97.

161. Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 2014;4:4026.

162. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, et al. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res 2014;2(4):332-40.

163. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, et al. Risk of ovarian cancer and the NF-kappaB pathway: genetic association with IL1A and TNFSF10. Cancer Res 2014;74(3):852-61.

164. Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD, et al. Variation in NF-kappaB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2014;23(7):1421-7.

165. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol 2014;25(8):1536-43.

166. Ali AM, Schmidt MK, Bolla MK, Wang Q, Gago-Dominguez M, Castelao JE, et al. Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases. Cancer Epidemiol Biomarkers Prev 2014;23(6):934-45.

167. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014;46(10):1103-9.

168. Ahsan H, Halpern J, Kibriya MG, Pierce BL, Tong L, Gamazon E, et al. A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol Biomarkers Prev 2014;23(4):658-69.

169. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013;4:1628.

170. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45(4):362-70.

171. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 2013;4:1627.

172. Nickels S, Truong T, Hein R, Stevens K, Buck K, Behrens S, et al. Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genet 2013;9(3):e1003284.

173. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013;45(4):353-61.

174. Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013.

175. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013;45(4):392-8.

176. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, et al. Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. Am J Hum Genet 2013.

177. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45(4):385-91.

178. Dunlop MG, Tenesa A, Farrington SM, Ballereau S, Brewster DH, Koessler T, et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals. Gut 2013;62(6):871-81.

179. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013;45(4):371-84.

180. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 2012;21(2):456-62.

181. Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012;107(5):800-7.

182. Weischer M, Nordestgaard BG, Pharoah P, Bolla MK, Nevanlinna H, Van’t Veer LJ, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012;30(35):4308-16.

183. Warren H, Dudbridge F, Fletcher O, Orr N, Johnson N, Hopper JL, et al. 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2012.

184. Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, et al. 19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus. Cancer Res 2012;72(7):1795-803.

185. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486(7403):400-4.

186. Spain SL, Carvajal-Carmona LG, Howarth KM, Jones AM, Su Z, Cazier JB, et al. Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. Hum Mol Genet 2012;21(4):934-46.

187. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 2012;21(24):5373-84.

188. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012.

189. Quesne JL, Jones J, Warren J, Dawson SJ, Ali HR, Bardwell H, et al. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol 2012;227(3):306-14.

190. Poole EM, Gates MA, High BA, Chanock SJ, Cramer DW, Cunningham JM, et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control 2012.

191. Orr N, Lemnrau A, Cooke R, Fletcher O, Tomczyk K, Jones M, et al. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet 2012.

192. Martinez-Delgado B, Yanowsky K, Inglada-Perez L, de la Hoya M, Caldes T, Vega A, et al. Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. J Med Genet 2012.

193. Lu Y, Chen X, Beesley J, Johnatty SE, Defazio A, Lambrechts S, et al. Genome-wide association study for ovarian cancer susceptibility using pooled DNA. Twin Res Hum Genet 2012;15(5):615-23.

194. Long J, Zheng W, Xiang YB, Lose F, Thompson D, Tomlinson I, et al. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2012;21(6):980-7.

195. Li Y, Low HQ, Foo JN, Darabi H, Einarsdomicronttir K, Humphreys K, et al. Genetic Variants in ER Cofactor Genes and Endometrial Cancer Risk. PLoS ONE 2012;7(8):e42445.

196. Lambrechts D, Truong T, Justenhoven C, Humphreys MK, Wang J, Hopper JL, et al. 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat 2012;33(7):1123-32.

197. Houlston RS. COGENT (COlorectal cancer GENeTics) revisited. Mutagenesis 2012;27(2):143-51.

198. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012;44(3):312-8.

199. Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, et al. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012;21(17):3926-39.

200. Dunlop MG, Tenesa A, Farrington SM, Ballereau S, Brewster DH, Koessler T, et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals. Gut 2012.

201. Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012;44(7):770-76.

202. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer 2012.

203. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012;226(1):97-107.

204. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480(7375):99-103.

205. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 2011;103(3):250-63.

206. Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, Howarth K, et al. Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer. PLoS Genet 2011;7(6):e1002105.

207. Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C, et al. Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Res 2011;71(19):6240-49.

208. Stevens KN, Garcia-Closas M, Fredericksen Z, Kosel M, Pankratz VS, Hopper JL, et al. Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br J Cancer 2011;105(12):1934-9.

209. Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O’Mara T, et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 2011;43(5):451-54.

210. Scollen S, Luccarini C, Baynes C, Driver K, Humphreys MK, Garcia-Closas M, et al. TGF-{beta} Signaling Pathway and Breast Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev 2011;20(6):1112-9.

211. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 2011;43(1):60-5.

212. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011;17(11):3742-50.

213. Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, et al. LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. Cancer Res 2011;71(11):3896-903.

214. Permuth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, et al. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2011;20(8):1793-7.

215. Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, et al. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet 2011;20(11):2263-72.

216. O’Mara TA, Ferguson K, Fahey P, Marquart L, Yang HP, Lissowska J, et al. CHEK2, MGMT, SULT1E1 and SULT1A1 polymorphisms and endometrial cancer risk. Twin Res Hum Genet 2011;14(4):328-32.

217. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Hogdall E, et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer 2011;128(9):2063-74.

218. Milne RL, Lorenzo-Bermejo J, Burwinkel B, Malats N, Arias JI, Zamora MP, et al. 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. J Med Genet 2011;48(10):698-702.

219. Milne RL, Goode EL, Garcia-Closas M, Couch FJ, Severi G, Hein R, et al. Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer. Cancer Epidemiol Biomarkers Prev 2011;20(10):2222-31.

220. Lurie G, Wilkens LR, Thompson PJ, Shvetsov YB, Matsuno RK, Carney ME, et al. Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE 2011;6(6):e20703.

221. Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer 2011;128(4):936-43.

222. Lin WY, Camp NJ, Cannon-Albright LA, Allen-Brady K, Balasubramanian S, Reed MW, et al. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet 2011;48(7):477-84.

223. Li J, Humphreys K, Heikkinen T, Aittomaki K, Blomqvist C, Pharoah PD, et al. A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 2011;126(3):717-27.

224. Lacey JV, Jr., Yang H, Gaudet MM, Dunning A, Lissowska J, Sherman ME, et al. Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study. Gynecol Oncol 2011;120(2):167-73.

225. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011;43(8):785-91.

226. Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 2011;129(6):687-94.

227. Healey CS, Ahmed S, O’Mara TA, Ferguson K, Lambrechts D, Garcia-Dios DA, et al. Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis 2011;32(12):1862-6.

228. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011.

229. Figueroa JD, Garcia-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, et al. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011.

230. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011;20(16):3289-303.

231. Brisbin AG, Asmann YW, Song H, Tsai YY, Aakre JA, Yang P, et al. Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet 2011;12(1):156.

232. Beesley J, Pickett HA, Johnatty SE, Dunning AM, Chen X, Li J, et al. Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE 2011;6(9):e24987.

233. Batra J, Nagle CM, O’Mara T, Higgins M, Dong Y, Tan OL, et al. A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer 2011;11(1):119.

234. Amankwah EK, Wang Q, Schildkraut JM, Tsai YY, Ramus SJ, Fridley BL, et al. Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the ovarian cancer association consortium. PLoS ONE 2011;6(5):e19642.

235. Amankwah EK, Kelemen LE, Wang Q, Song H, Chenevix-Trench G, Beesley J, et al. Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2011;20(5):1028-31.

236. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011;13(6):R118.

237. Ali AM, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, et al. Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer 2011;104(4):693-9.

238. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, et al. CYP2D6 Gene Variants and Their Association with Breast Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev 2011;20(6):1255-8.

239. Udler MS, Ahmed S, Healey CS, Meyer K, Struewing J, Maranian M, et al. Fine scale mapping of the breast cancer 16q12 locus. Hum Mol Genet 2010;19(12):2507-15.

240. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010;42(6):504-7.

241. Tomlinson IP, Dunlop M, Campbell H, Zanke B, Gallinger S, Hudson T, et al. COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer 2010;102(2):447-54.

242. Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 2010;103(12):1875-84.

243. Terry KL, Vitonis AF, Hernandez D, Lurie G, Song H, Ramus SJ, et al. A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. Int J Mol Epidemiol Genet 2010;1(4):272-7.

244. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42(11):937-48.

245. Pooley KA, Tyrer J, Shah M, Driver KE, Leyland J, Brown J, et al. No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19(7):1862-5.

246. Pooley KA, Sandhu MS, Tyrer J, Shah M, Driver KE, Luben RN, et al. Telomere length in prospective and retrospective cancer case-control studies. Cancer Res 2010;70(8):3170-6.

247. Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, Beesley J, et al. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010;19(2):600-4.

248. Olson JE, Wang X, Goode EL, Pankratz VS, Fredericksen ZS, Vierkant RA, et al. Variation in genes required for normal mitosis and risk of breast cancer. Breast Cancer Res Treat 2010;119(2):423-30.

249. Milne RL, Gaudet MM, Spurdle AB, Fasching PA, Couch FJ, Benitez J, et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the Breast Cancer Association Consortium: a combined case-control study. Breast Cancer Res 2010;12(6):R110.

250. Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D, et al. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 2010;12(1):R10.

251. Lose F, Nagle CM, O’Mara T, Batra J, Bolton KL, Song H, et al. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol 2010;119(3):479-83.

252. Li J, Humphreys K, Darabi H, Rosin G, Hannelius U, Heikkinen T, et al. A genome-wide association scan on estrogen receptor -negative breast cancer. Breast Cancer Res 2010;12(6):R93.

253. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010;467(7317):832-8.

254. Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM, Kobel M, et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010;19(7):1822-30.

255. Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, et al. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility “hot-spot”. PLoS Genet 2010;6(7):e1001016.

256. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet 2010;42(11):973-77.

257. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42(10):874-79.

258. Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, et al. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev 2010;19(9):2143-51.

259. Elks CE, Perry JR, Sulem P, Chasman DI, Franceschini N, He C, et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet 2010;42(12):1077-85.

260. Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, et al. ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. Cancer Epidemiol Biomarkers Prev 2010;19(1):245-50.

261. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010;103(5):668-75.

262. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42(10):880-4.

263. Bolton KL, Garcia-Closas M, Pfeiffer RM, Duggan MA, Howat WJ, Hewitt SM, et al. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2010;19(4):992-9.

264. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7(5):e1000279.

265. Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, et al. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst 2010;102(9):650-62.

266. Azzato EM, Pharoah PD, Harrington P, Easton DF, Greenberg D, Caporaso NE, et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev 2010;19(4):1140-3.

267. Azzato EM, Lee AJ, Teschendorff A, Ponder BA, Pharoah PD, Caldas C, et al. Common germ-line polymorphism of C1QA and breast cancer survival. Br J Cancer 2010;102(8):1294-9.

268. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010;42(10):885-92.

269. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12(4):R64.

270. Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet 2009;18(9):1692-703.

271. Udler MS, Azzato EM, Healey CS, Ahmed S, Pooley KA, Greenberg D, et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 2009;125(11):2687-96.

272. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009;41(9):996-1000.

273. Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, et al. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet 2009;18(12):2297-304.

274. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van’t Veer LJ, Pharoah PD, et al. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 2009;11(6):R89.

275. Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2009;69(6):2349-57.

276. Quaye L, Tyrer J, Ramus SJ, Song H, Wozniak E, DiCioccio RA, et al. Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. PLoS ONE 2009;4(6):e5983.

277. Quaye L, Song H, Ramus SJ, Gentry-Maharaj A, Hogdall E, DiCioccio RA, et al. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer 2009;100(6):993-1001.

278. Quaye L, Dafou D, Ramus SJ, Song H, Gentry-Maharaj A, Notaridou M, et al. Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet 2009;18(10):1869-78.

279. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, et al. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer 2009;100(2):412-20.

280. Milne RL, Benitez J, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst 2009;101(14):1012-8.

281. Mavaddat N, Dunning AM, Ponder BA, Easton DF, Pharoah PD. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18(1):255-9.

282. Koessler T, Azzato EM, Perkins B, Macinnis RJ, Greenberg D, Easton DF, et al. Common germline variation in mismatch repair genes and survival after a diagnosis of colorectal cancer. Int J Cancer 2009;124(8):1887-91.

283. Kelemen LE, Wang X, Fredericksen ZS, Pankratz VS, Pharoah PD, Ahmed S, et al. Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18(6):1864-8.

284. Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Phelan CM, Anderson S, et al. Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18(3):935-44.

285. Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, et al. Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2009;18(5):1610-6.

286. Gaudet MM, Hunter K, Pharoah P, Dunning AM, Driver K, Lissowska J, et al. Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. Int J Cancer 2009;124(7):1716-20.

287. Field HI, Scollen SA, Luccarini C, Baynes C, Morrison J, Dunning AM, et al. Seq4SNPs: new software for retrieval of multiple, accurately annotated DNA sequences, ready formatted for SNP assay design. BMC Bioinformatics 2009;10:180.

288. Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009;18(6):1131-9.

289. Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, et al. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer 2009;101(8):1461-8.

290. Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE, et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 2009;100(11):1806-11.

291. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009;41(5):585-90.

292. Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, et al. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res 2009;15(6):2181-91.

293. Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008;40(5):623-30.

294. Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, Dowsett M, et al. Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17(12):3490-8.

295. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008;40(5):631-7.

296. Song H, Koessler T, Ahmed S, Ramus SJ, Kjaer SK, Dicioccio RA, et al. Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. Cancer Res 2008;68(21):8837-42.

297. Song H, Hogdall E, Ramus SJ, Dicioccio RA, Hogdall C, Quaye L, et al. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. Clin Cancer Res 2008;14(4):1090-5.

298. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008;123(2):380-8.

299. Quaye L, Gayther SA, Ramus SJ, Di Cioccio RA, McGuire V, Hogdall E, et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res 2008;14(18):5833-9.

300. Pooley KA, Baynes C, Driver KE, Tyrer J, Azzato EM, Pharoah PD, et al. Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17(12):3482-9.

301. Pearce CL, Wu AH, Gayther SA, Bale AE, Beck PA, Beesley J, et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer 2008;98(2):282-8.

302. Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, et al. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 2008;17(12):3567-72.

303. Mann A, Hogdall E, Ramus SJ, DiCioccio RA, Hogdall C, Quaye L, et al. Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients. Eur J Cancer 2008;44(15):2259-65.

304. Koessler T, Oestergaard MZ, Song H, Tyrer J, Perkins B, Dunning A, et al. Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008;57(8):1097-101.

305. Kelemen LE, Couch FJ, Ahmed S, Dunning AM, Pharoah PD, Easton DF, et al. Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Res 2008;10(6):R98.

306. Kalmyrzaev B, Pharoah PD, Easton DF, Ponder BA, Dunning AM. Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17(12):3618-20.

307. Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu-Amero S, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 2008;17(17):2633-43.

308. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008;40(12):1426-35.

309. Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008;100(13):962-6.

310. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4(4):e1000054.

311. Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, Sutter C, et al. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst 2008;100(6):437-42.

312. Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, et al. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 2008;111(1):139-44.

313. Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, Tyrer J, et al. Association of single-nucleotide polymorphisms in the Cell Cycle genes with breast cancer in the British population. Carcinogenesis 2008;29(2):333-41.

314. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8(1):153.

315. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008;26(20):3310-6.

316. Azzato EM, Driver KE, Lesueur F, Shah M, Greenberg D, Easton DF, et al. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res 2008;10(3):R47.

317. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98(8):1457-66.

318. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M, et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 2007;25(21):3015-23.

319. Song H, Ramus SJ, Kjaer SK, Hogdall E, Dicioccio RA, Whittemore AS, et al. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS ONE 2007;2(3):e268.

320. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 2007;67(19):9584-90.

321. Samuelson DJ, Hesselson SE, Aperavich BA, Zan Y, Haag JD, Trentham-Dietz A, et al. Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk. Proc Natl Acad Sci U S A 2007;104(15):6299-304.

322. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA. Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 2007;3(3):e42.

323. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007;67(7):3027-35.

324. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447(7148):1087-93.

325. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39(3):352-8.

326. Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, Kjaer SK, et al. Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev 2007;16(12):2557-65.

327. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, et al. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 2007;9(2):R27.

328. Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006;15(11):2107-14.

329. Song H, Ramus SJ, Shadforth D, Quaye L, Kjaer SK, Dicioccio RA, et al. Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Res 2006;66(20):10220-6.

330. Song H, Ramus SJ, Quaye L, DiCioccio RA, Tyrer J, Lomas E, et al. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 2006;27(11):2235-42.

331. Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev 2006;15(4):675-82.

332. Oestergaard MZ, Tyrer J, Cebrian A, Shah M, Dunning AM, Ponder BA, et al. Interactions between genes involved in the antioxidant defence system and breast cancer risk. Br J Cancer 2006;95(4):525-31.

333. Lesueur F, Song H, Ahmed S, Luccarini C, Jordan C, Luben R, et al. Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population. Br J Cancer 2006;94(12):1921-6.

334. Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res 2006;66(2):1177-80.

335. El-Tanani MK, Campbell FC, Crowe P, Erwin P, Harkin DP, Pharoah P, et al. BRCA1 suppresses osteopontin-mediated breast cancer. Journal of Biological Chemistry 2006;281(36):26587-601.

336. Cebrian A, Pharoah PD, Ahmed S, Smith PL, Luccarini C, Luben R, et al. Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res 2006;66(2):1225-33.

337. Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL, et al. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006;27:1661-69.

338. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006;12(8):2468-75.

339. Benusiglio PR, Pharoah PD, Smith PL, Lesueur F, Conroy D, Luben RN, et al. HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer 2006;95(12):1689-95.

340. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006;15(1):1-10.

341. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005;37(10):1055-62.

342. Lesueur F, Pharoah PD, Laing S, Ahmed S, Jordan C, Smith PL, et al. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet 2005;14(16):2349-56.

343. Kuschel B, Chenevix-Trench G, Spurdle AB, Chen X, Hopper JL, Giles GG, et al. Common polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14(7):1828-31.

344. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, et al. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90(11):6268-74.

345. Callagy G, Pharoah P, Chin SF, Sangan T, Daigo Y, Jackson L, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005;205(3):388-96.

346. Benusiglio PR, Luccarini C, Ajai O, Ponder BA, Pharoah PD. Reply: a bias in genotyping of the ERBB2 (HER2) Ile655Val variant (letter). Carcinogenesis 2005;26(12):2213.

347. Benusiglio PR, Lesueur F, Luccarini C, McIntosh J, Luben RN, Smith P, et al. Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs. BMC Cancer 2005;5(1):81.

348. Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 2005;117(4):611-8.

349. Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005;42(7):602-3.

350. Neuhausen S, Dunning A, Steele L, Yakumo K, Hoffman M, Szabo C, et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 2004;108(3):477-8.

351. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2004;96(24):1866-9.

352. Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, et al. STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13(10):1589-94.

353. CHEK2 Breast Cancer Case-Control Consortium, Pharoah PDP. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from nine studies. Am J Hum Genet 2004;74:1175-82.

354. 329 Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91(8):1580-90.

355. Kuschel B, Auranen A, Gregory CS, Day NE, Easton DF, Ponder BA, et al. Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12(8):809-12.

356. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, et al. A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63(10):2610-5.

357. Chang-Claude J, Dunning A, Schnitzbauer U, Galmbacher P, Tee L, Wjst M, et al. The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. Int J Cancer 2003;103(6):779-83.

358. Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, et al. BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk. Int J Cancer 2003;103(3):427-30.

359. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117-30.

360. Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002;11(12):1399-407.

361. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BAJ, et al. Effect of germline genetic variation on breast cancer survival in a population-based study. Cancer Res 2002;62(11):3052-57.

362. Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4(1):R2.

363. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86(1):76-83.

364. Kuschel B, Gayther SA, Easton DF, Ponder BAJ, Pharoah PDP. Apparent human BRCA1 knockout caused by mis-priming during PCR: implications for genetic testing. Genes Chromosomes Cancer 2001;31:96-98.

365. Basham VM, Pharoah PDP, Healey CS, Luben RN, Day NE, Easton DF, et al. Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk. Carcinogenesis 2001;22:1797-800.

366. Antoniou AC, Pharoah PDP, McMullen G, Day NE, Ponder BAJ, Easton DF. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population based study. Genet Epidemiol 2001;21:1-18.

367. Pharoah PD, Lipscombe JM, Redman KL, Day NE, Easton DF, Ponder BA. Familial predisposition to breast cancer in a British population: implications for prevention. Eur J Cancer 2000;36(6):773-9.

368. Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000;26(3):362-64.

369. Healey CS, Dunning AM, Durocher F, Teare D, Pharoah PD, Luben RN, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21(2):189-93.

370. Anglian Breast Cancer Study Group, Pharoah P. Prevalence and penetrance of BRCA1 and BRCA2 in a population based series of breast cancer cases. Br J Cancer 2000;83:1301-08.

371. Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healey CS, et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 1999;20(11):2131-35.

372. Dunning AM, Healey CS, Pharoah PDP, Foster NA, Lipscombe JM, Redman KL, et al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 1998;77(11):2045-47.